Sinopharm clinical trials

The registry lists 95 studies whose lead sponsor is Sinopharm or one of 6 companies grouped under it. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 3, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 95. Browse all 95 →

• A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal AntibodyNot yet recruitingNCT07445815Phase 2

  Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm

• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 1

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionEnrolling by invitationNCT07149454Phase 1

  Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm

• Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term InfantsNot yet recruitingNCT07363837Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT06194656Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsRecruitingNCT05262010Phase 3

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm

• Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveNot yet recruitingNCT07327398Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveRecruitingNCT07302256Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.RecruitingNCT06298071Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06990464Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.RecruitingNCT07205198Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.RecruitingNCT06298058Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.RecruitingNCT06512116Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy IndividualsRecruitingNCT06932523Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06985368Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingNCT07253675Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A16 Injection in Healthy AdultsRecruitingNCT07106918Early Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineRecruitingNCT06771479Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule BridgingActive, not recruitingNCT06632912Phase 3

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm

• Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)CompletedNCT05916326Phase 3

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm

• A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedNCT04869592Phase 1/2

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm

• Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and AboveCompletedNCT05408312Phase 1

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm

• Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedActive, not recruitingNCT05091619Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.CompletedNCT06342349Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03755427Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03369808Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of A Quadrivalent Influenza VaccineCompletedNCT03744104Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of Peginterferon in Patients With Herpes ZosterCompletedNCT05492591Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Comparing SIBP-04 and Bevacizumab in Healthy Male SubjectsCompletedNCT04135898Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldCompletedNCT05158777Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.CompletedNCT05203601Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerCompletedNCT03989037Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic HyperuricemiaCompletedNCT05302388Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 YearsCompletedNCT04072497Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Quadrivalent Influenza Virus Split VaccineCompletedNCT04363359Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, LiveCompletedNCT05161845Phase 4

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 YearsCompletedNCT05138705Phase 4

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of AgeActive, not recruitingNCT05839301Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineActive, not recruitingNCT05669625Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), InactivatedActive, not recruitingNCT04863638Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveActive, not recruitingNCT05365724Phase 1/2

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and AboveCompletedNCT04917523Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and AboveActive, not recruitingNCT05382871Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveCompletedNCT04510207Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and AboveActive, not recruitingNCT05374954Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)Status unknownNCT05293548Phase 2

  Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm